Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 24, Issue 5, 2011, Pages 235-243

  Brusasco, Vito ^a   Canonica, G Walter ^a   Negro, Roberto Dal ^b   Scano, Giorgio ^c   Paggiaro, Pierluigi ^d   Fabbri, Leonardo M ^e   Barisione, Giovanni ^f   D'Amato, Gennaro ^g   Varoli, Guido ^h   Baroffio, Michele ^a   Milanese, Manlio ⁱ   Mereu, Carlo ⁱ   Crimi, Emanuele ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Hospital of Bussolengo (Verona)   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h CHIESI FARMACEUTICI S P A   (Italy)

ⁱ SANTA CORONA HOSPITAL   (Italy)

Author keywords

inhaler

Indexed keywords

FLUORINATED HYDROCARBON; FORMOTEROL; PLACEBO; PROPELLANT;

6 MINUTE WALKING TEST; ABSENCE OF SIDE EFFECTS; AEROSOL; AGED; AIRWAY CONDUCTANCE; AIRWAY OBSTRUCTION; ARTICLE; BORG SCALE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LUNG VOLUME; MALE; METERED DOSE INHALER; MULTIPLE CYCLE TREATMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SPIROMETRY; TOTAL LUNG CAPACITY;

AEROSOLS; AGED; AIRWAY OBSTRUCTION; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INSPIRATORY CAPACITY; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 80053486133     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0862     Document Type: Article

References (28)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2008). Available at: http://www.goldcopd.org.
2. O'Donnell DE, Lam M, and Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:542-549. (Pubitemid 29380670)
3. O'Donnell DE, Revill SM, and Webb KA: Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164: 770-777. (Pubitemid 32881912)
4. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, and Lisboa C: Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J. 2000;16:269-275. (Pubitemid 30627482)
5. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, and Celli BR: Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minutewalk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1395-1399. (Pubitemid 32506605)
6. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, and Celli BR: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591-597. (Pubitemid 40365414)
7. Pellegrino R, and Brusasco V: On the causes of lung hyperinflation during bronchoconstriction. Eur Respir J. 1997; 10:468-475. (Pubitemid 27063870)
8. Pellegrino R, Rodarte JR, and Brusasco V: Assessing the reversibility of airway obstruction. Chest. 1998;114:1607-1612. (Pubitemid 128487483)
9. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B,Make B, and Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840. (Pubitemid 38807355)
10. O'Donnell DE, Voduc N, Fitzpatrick M, and Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86-94. (Pubitemid 39029073)
11. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, and Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003;21:86-94.
12. Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med. 2002;96:S3-S8. (Pubitemid 40023468)
13. Woodcock A, Acerbi D, and Poli G: Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir Med. 2002;96:S9-S15. (Pubitemid 40023469)
14. Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, and Woodcock A: Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebocontrolled, crossover study. Br J Clin Pharmacol. 2004;58: 359-366. (Pubitemid 39312459)
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: Standardisation of spirometry. Eur Respir J. 2005;26: 319-338. (Pubitemid 41079078)
16. Wanger J, Clausen JL, Coates A, Pedersen O, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, and Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511-522. (Pubitemid 41264217)
17. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, and Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6:5-40.
18. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
19. Borg GAV: Psychophysical basis of perceived exertion. Med Sci Sports. 1982;14:377-381.
20. Ebbutt AF and Frith L: Practical issues in equivalence trials. Stat Med 1998;17:1691-1701. (Pubitemid 28409925)
21. Maesen BL, Westermann CJ, Duurkens VA, and van den Bosch JM: Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J. 1999;13:1103-1108. (Pubitemid 29288936)
22. Liesker JJ, Van De Velde V, Meysman M, Vincken W, Wollmer P, Hansson L, Kerstjens HA, Qvint U, and Pauwels RA: Effects of formoterol (Oxis Turbohaler) and ipratropium on exercise capacity in patients with COPD. Respir Med. 2002;96:559-566.
23. Tunon-de-Lara J-M, Laurent F, Giraud V, Perez T, Aguilaniu B, Meziane H, Basset-Merle A, and Chanez P: Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol. 2007;119:583-590. (Pubitemid 46335813)
24. Santus P, Centanni S, Verga M, Di Marco F, Matera MG, and Cazzola M: Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/ formoterol on the degree of resting pulmonary hyperinflation. Respir Med. 2006;100:1277-1281. (Pubitemid 43793054)
25. Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, and Cornelissen PJ: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129: 509-517.
26. Ramirez-Venegas A, Ward J, Lentine T, and Mahler DA: Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest. 1997;112:336-340. (Pubitemid 27349421)
27. O'Donnell DE, Lam M, and Webb KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1557-1565.
28. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, and O'Donnell D: Improvements in symptom-limited exercise performance over 8 h with oncedaily tiotropium in patients with COPD. Chest. 2005;128: 1168-1178. (Pubitemid 41324392)